2025-11-22 - Analysis Report
Okay, here's an analysis of SUI-USD (Sui) based on the provided data, formatted for a report:

**Report: SUI-USD (Sui) Analysis**

**1. Performance Overview & Comparative Analysis**

*   **Company Description:**  Sui is [Need to fill in Company Description based on the company name].
*   **Key Metrics:**
    *   SUI-USD Cumulative Return: -82.03%
    *   S&P 500 (VOO) Cumulative Return: 19.44%
    *   Absolute Divergence: -101.47%
    *   Relative Divergence: 4.9
*   **Divergence Analysis:** SUI-USD significantly underperformed the S&P 500 (VOO) over the observed period. The absolute divergence indicates a substantial difference in returns. The relative divergence of 4.9 suggests that SUI-USD's underperformance is near the lower end of its historical range compared to VOO.

*   **Alpha, Beta Analysis:**

| Year      | CAGR      | MDD     | Alpha     | Beta    | Cap(B) |
| ----------- | --------- | -------- | --------- | ------- | ------ |
| 2023-2025 | -82.0%    | 95.2%    | -99.0%   | 0.0     | 0.0    |

    *   **Analysis:** The CAGR of -82.0% signifies a substantial loss over the period. The MDD of 95.2% indicates very high volatility and significant potential for loss. The negative Alpha and Beta of 0.0 suggest that the stock's performance is independent of the market.

**2. Recent Price Action**

*   **Current Price:** 0.0003001941
*   **Last Market Data:** Price: 0.0003001941, Previous Close: 0.0003001941, Change: 0.0
*   **Moving Averages:**
    *   5-Day MA: 0.0003
    *   20-Day MA: 0.0003
    *   60-Day MA: 0.0004
*   **Analysis:** The price has remained relatively stable in the very short term. However, the 60-day moving average is higher than the 5-day and 20-day averages, potentially indicating a downtrend. The Last-market data also shows no change in price, meaning there are no current price movements.

**3. Technical Indicators & Signals**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment Recommended)
*   **RSI:** 42.71
*   **PPO:** -1.36
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (10 shares - Caution - MRI:0.70) (Cash Ratio: 0% on 2024-05-27)
*   **Recent (20-day) Relative Divergence Change:** +0.7 (Short-term increase)
*   **Expected Return:** 292.0%
*   **Analysis:**
    *   The MRI suggests a medium level of investment risk.
    *   The RSI of 42.71 is in neutral territory, not indicating overbought or oversold conditions.
    *   The negative PPO suggests a slightly bearish trend.
    *   The Hybrid Signal recommends buying, but with caution due to the MRI.
    *   The increasing relative divergence suggests some recent positive momentum.
    *   The extremely high expected return should be viewed cautiously, as it is a long-term projection and may not be realistic.

**4. News & Events**

*   **Recent News:**
    *   [2025-11-21] After Dozens Hospitalized, Victims of Oklahoma AirGas Ammonia Leak File Lawsuit Through Clayton B. Bruner Law Firm (GlobeNewswire) - [https://finance.yahoo.com/news/dozens-hospitalized-victims-oklahoma-airgas-220200220.html](https://finance.yahoo.com/news/dozens-hospitalized-victims-oklahoma-airgas-220200220.html)
*   **Analyst Opinions:** Analyst Consensus: Not Available
*   **Analysis:** The news of the lawsuit related to an ammonia leak at AirGas (assuming SUI-USD is linked or related to AirGas due to the news mentioning it) is a significant negative event. This could significantly impact investor sentiment and the stock's performance.

**5. Conclusion**

SUI-USD has significantly underperformed the S&P 500. While some technical indicators show a slight positive trend, the negative news regarding the ammonia leak lawsuit presents a major risk. The high expected return should be viewed skeptically. Given the significant underperformance, high volatility, and negative news, a **highly cautious** approach is warranted. Further due diligence is required, especially to understand the company's fundamentals and its relation to the reported news event.

**Disclaimer:** *This analysis is based solely on the provided data and does not constitute financial advice.  Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.*
